Throat and Oropharyngeal HOCl Applications: A Novel Approach to Oral and Upper Respiratory Health

The throat and oropharynx are critical entry points for pathogens and are susceptible to infections, inflammation, and irritation. Common conditions such as pharyngitis, tonsillitis, and viral upper respiratory infections (URIs) present significant health burdens worldwide, accounting for millions of healthcare visits annually and contributing to substantial morbidity in both pediatric and adult populations. Traditional treatments often focus on symptom management or systemic antibiotics, which can have limitations, adverse side effects, and contribute to the growing global crisis of antimicrobial resistance. Hypochlorous acid (HOCl) is emerging as a safe, effective, and versatile agent for soothing throat discomfort, reducing microbial load, and potentially preventing upper respiratory infections. Its potent antimicrobial activity combined with excellent tolerability and biocompatibility makes it a promising therapeutic option for oropharyngeal health. This article explores the applications of HOCl in throat and oropharyngeal care, reviewing the current scientific evidence supporting its use and comparing it to conventional therapeutic agents.

The Oropharyngeal Environment: A Gateway for Pathogens

The oropharynx and throat are constantly exposed to environmental pathogens via inhalation and ingestion. The moist mucosal lining houses a complex microbiome comprising hundreds of bacterial species, but it is also a common site for the establishment of bacteria and viruses that cause infections. The oropharyngeal mucosa serves as the first line of immunological defense, yet its warm, moist environment also makes it an ideal colonization surface for pathogenic microorganisms. Understanding the dynamics of this environment is crucial for developing targeted therapeutic interventions that can reduce pathogenic burden while preserving beneficial commensal flora.

• Pharyngitis and Tonsillitis: Often caused by viral infections (e.g., rhinoviruses, adenoviruses, coronaviruses) but can also be bacterial (e.g., Group A Streptococcus). Symptoms include sore throat, difficulty swallowing, and fever. Bacterial pharyngitis requires antibiotic treatment, while viral cases are managed supportively, creating a clinical need for effective non-antibiotic adjuncts.
• Oral Thrush: A fungal infection (Candida albicans) common in infants, immunocompromised individuals, or those using inhaled corticosteroids. It presents as white, curd-like plaques on the oral mucosa and can cause significant discomfort and difficulty eating.
• Viral Upper Respiratory Infections (URIs): Including the common cold, characterized by sore throat, nasal congestion, and cough. These infections represent the most common acute illness in humans and are a leading cause of missed work and school.
• Post-Surgical Recovery: Following tonsillectomy or other oropharyngeal procedures, maintaining a clean, infection-free environment is crucial for healing. The surgical site is particularly vulnerable to bacterial colonization, which can lead to secondary infection, increased pain, and delayed recovery.

Hypochlorous Acid (HOCl): Properties Relevant to Oropharyngeal Health

HOCl is the endogenous oxidant produced by neutrophils during the respiratory burst, serving as a primary effector molecule of the innate immune system. In the body, it is generated when myeloperoxidase catalyzes the oxidation of chloride ions by hydrogen peroxide. This natural molecule has been harnessed in stabilized pharmaceutical formulations for topical therapeutic use, offering unique advantages for oropharyngeal applications (Wang et al., 2020).

• Broad-Spectrum Antimicrobial Efficacy: HOCl effectively neutralizes a wide range of bacteria (including Staphylococcus aureus, Streptococcus species, and Pseudomonas aeruginosa), viruses (e.g., influenza, coronaviruses, rhinoviruses), and fungi (e.g., Candida albicans). This broad action is vital for targeting the diverse pathogens that cause throat and oropharyngeal infections. Recent research has demonstrated that HOCl achieves rapid bactericidal effects, with studies showing complete inactivation of oral pathogens within minutes of exposure (Tazawa et al., 2023). Furthermore, HOCl has demonstrated efficacy against SARS-CoV-2 surrogates, suggesting potential utility in reducing viral load in the oropharynx (Tazawa et al., 2023).
• Rapid Action: HOCl works quickly, inactivating pathogens upon contact. Studies have demonstrated that stabilized HOCl solutions achieve complete microbial kill within 12 seconds to 2 minutes of exposure, depending on concentration and target organism (Sakarya et al., 2014). This rapid onset of action makes it particularly suitable for acute sore throat relief and immediate reduction of microbial burden.
• Non-Cytotoxic and Non-Irritating: At physiological pH and appropriate concentrations (typically 50-200 ppm for mucosal applications), HOCl is safe for human mucosal tissues. Unlike stronger antiseptics or alcohol-based solutions, it does not cause burning, stinging, or damage to delicate mucous membranes. This makes it ideal for soothing sore throats and for use on inflamed or compromised mucosal surfaces (Sakarya et al., 2014). Cytotoxicity studies have confirmed that therapeutic concentrations of HOCl do not impair fibroblast or keratinocyte migration, which is essential for tissue healing (Sakarya et al., 2014).
• Anti-inflammatory Properties: Emerging research suggests HOCl may modulate the inflammatory response, helping to reduce swelling and discomfort associated with infections. HOCl has been shown to downregulate pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), while promoting resolution of inflammation through activation of the NRF2-HO-1 pathway (Wang et al., 2020). This dual antimicrobial and anti-inflammatory action makes HOCl uniquely suited for managing inflammatory oropharyngeal conditions.
• No Resistance Development: Its multi-target oxidative mechanism prevents microbial resistance, a growing concern with antibiotics and some traditional antiseptics. Unlike conventional antibiotics that target specific metabolic pathways or cell wall synthesis, HOCl exerts its antimicrobial effects through non-specific oxidation of cellular components including proteins, lipids, and nucleic acids, making the development of resistance virtually impossible (Wang et al., 2020).
• Odor Neutralization: HOCl can neutralize volatile sulfur compounds produced by anaerobic oral bacteria, helping to combat oral malodor (halitosis). This property is particularly relevant for patients with chronic tonsillitis or post-nasal drip who experience persistent bad breath.
• Biofilm Disruption: HOCl has demonstrated significant antibiofilm activity, effectively penetrating and disrupting established bacterial biofilms. This is particularly relevant for oropharyngeal infections where biofilm formation contributes to chronicity and treatment resistance (Sakarya et al., 2014).

Therapeutic Applications in Throat and Oropharyngeal Care

1. Sore Throat Relief and Infection Management

Sore throat, or odynophagia, is one of the most common complaints in primary care and otolaryngology practice. While most cases are viral in etiology, the discomfort can be severe and significantly impact quality of life. HOCl offers a novel approach to sore throat management that addresses both the microbial cause and the inflammatory symptoms.

• Mechanism: Swishing or gargling with HOCl solutions can directly target pathogens causing pharyngitis and tonsillitis, reducing bacterial load and viral presence in the oropharynx. The solution coats the mucosal surface, providing sustained contact time for antimicrobial action.
• Clinical Evidence: A randomized controlled trial by Gun (2018) demonstrated that low-concentration HOCl spray provided statistically significant improvement in sore throat symptoms compared to placebo saline spray. Patients receiving HOCl reported faster pain resolution and improved swallowing function, supporting its clinical utility for acute pharyngitis management.
• Benefits: May alleviate sore throat pain, reduce inflammation, and shorten the duration of viral URIs by neutralizing pathogens on contact. Its soothing effect provides symptomatic relief without the numbing agents or anesthetics found in some commercial throat sprays.

2. Oral Thrush (Candida) Management

Oropharyngeal candidiasis, commonly known as oral thrush, is caused by overgrowth of Candida albicans and particularly affects immunocompromised patients, denture wearers, and those using inhaled corticosteroids. Conventional treatment relies on antifungal medications, which can interact with other medications and may be associated with hepatotoxicity.

• Mechanism: HOCl’s fungicidal properties can help control the overgrowth of Candida albicans in the oral cavity. The oxidative mechanism damages fungal cell walls and membranes, leading to cell death.
• Benefits: Can be used as an adjunct to antifungal medications to reduce fungal burden and prevent recurrence. Its gentle nature makes it suitable for oral use, even in immunocompromised patients who may have heightened mucosal sensitivity. The selective antimicrobial properties of HOCl allow it to target pathogenic fungi while preserving beneficial commensal bacteria (Goodman, 2024).

3. Post-Tonsillectomy Recovery

Tonsillectomy remains one of the most commonly performed surgical procedures in otorhinolaryngology, with over 530,000 procedures performed annually in the United States alone. Postoperative recovery is characterized by significant pain, risk of secondary hemorrhage, and potential for surgical site infection. The tonsillar bed is particularly susceptible to bacterial colonization during the healing period, which can contribute to fibrinolysis and secondary bleeding.

• Application: Gentle gargling or spraying with HOCl post-operatively can help maintain the surgical site’s cleanliness, reduce bacterial contamination, and soothe throat discomfort. The use of oral rinses following tonsillectomy has been shown to improve recovery outcomes by reducing bacterial colonization of the surgical site (Cooper & McGeorge, 2016).
• Benefits: Potentially aids in preventing post-tonsillectomy infections and promotes a more comfortable recovery. The anti-inflammatory properties of HOCl may help reduce postoperative edema and pain, while its antimicrobial action reduces the risk of secondary infection that could lead to hemorrhage. Unlike some traditional mouthwashes, HOCl does not irritate the healing wound or cause discomfort upon application.
• Evidence Context: A Cochrane review on oral rinses for post-tonsillectomy recovery identified various agents used for this purpose, though specific HOCl studies in this population remain an area for future research (Fedorowicz et al., 2020). The established safety profile and antimicrobial efficacy of HOCl suggest it warrants investigation as a post-tonsillectomy rinse.

4. General Oral and Oropharyngeal Hygiene

Maintaining optimal oral and oropharyngeal hygiene extends beyond brushing and flossing. The oropharynx harbors a complex microbial ecosystem that, when dysbiotic, can contribute to local and systemic disease. Regular use of targeted antimicrobial agents can help maintain microbial balance and reduce the risk of opportunistic infections.

• Application: Regular use as a mouth rinse can supplement brushing and flossing by reducing overall microbial load in the oropharynx. A randomized controlled trial by Lin et al. (2023) demonstrated that HOCl mouthwash significantly reduced salivary bacterial counts, including Staphylococcus aureus, in patients with periodontal disease.
• Benefits: Contributes to a healthier oral microbiome, reduces the risk of infections, and helps manage halitosis. Unlike chlorhexidine, which is associated with tooth staining and taste alteration with prolonged use, HOCl does not cause these cosmetic side effects, making it more suitable for long-term daily use (Aherne et al., 2022).
• Microbiome Preservation: A significant advantage of HOCl over conventional antiseptics is its selective antimicrobial activity. Research indicates that HOCl mouth rinse preserves commensal oral bacteria while effectively killing pathogenic species, maintaining the ecological balance necessary for oral health (Goodman, 2024).

Comparison with Traditional Oropharyngeal Agents

Understanding how HOCl compares to established oropharyngeal treatments helps clinicians and patients make informed choices about throat care interventions.

• Saltwater Gargle: Soothing for sore throats due to osmotic effects but lacks significant antimicrobial action against specific pathogens. While it can provide temporary symptom relief, it does not address the underlying microbial cause of infections.
• Antiseptic Mouthwashes (e.g., Cetylpyridinium Chloride, Essential Oils): Offer some antimicrobial benefit but may not be as potent or broad-spectrum as HOCl against key pathogens like MRSA or specific viruses. Some can cause irritation and are less effective against biofilm-associated bacteria.
• Chlorhexidine (CHX) Mouthwashes: Highly effective broad-spectrum antiseptic but associated with significant tooth staining, taste alteration, calculus formation, and potential mucosal irritation. Often recommended for short-term use only due to these side effects. Aherne et al. (2022) demonstrated that HOCl achieved superior biofilm reduction compared to CHX without the adverse effects on dental hard tissues.
• Povidone-Iodine: Effective against a broad range of pathogens but can cause thyroid dysfunction with prolonged use, allergic reactions, and significant tissue irritation. It is generally not recommended for routine oropharyngeal use.
• Antibiotics: Reserved for bacterial infections (e.g., strep throat), not effective against viral URIs or fungal infections. Overuse leads to resistance, disruption of the microbiome, and potential adverse effects including gastrointestinal disturbance and allergic reactions.
• HOCl: Provides potent, broad-spectrum, rapid antimicrobial and antiviral action with excellent safety and tolerability, making it suitable for a wider range of applications and potentially longer-term use without significant side effects (Sakarya et al., 2014). Its natural origin and biocompatibility profile distinguish it from synthetic antiseptics.

Safety Profile and Tolerability Considerations

The safety of any agent intended for oropharyngeal use is paramount, given the sensitivity of mucosal tissues and the potential for systemic absorption. HOCl has an exceptionally favorable safety profile that has been established through both in vitro and in vivo investigations. Therapeutic concentrations of HOCl (typically 50-200 ppm) have been shown to be non-cytotoxic to human keratinocytes, fibroblasts, and mucosal epithelial cells (Sakarya et al., 2014). Importantly, HOCl does not impair wound healing processes; rather, it has been shown to promote fibroblast and keratinocyte migration, which is beneficial for tissue repair (Sakarya et al., 2014).

Clinical studies have reported minimal to no adverse events with topical HOCl use, even with repeated application over extended periods. Unlike alcohol-based products, HOCl does not cause pain or burning upon application to inflamed or damaged mucosa. It is non-sensitizing and has not been associated with allergic contact dermatitis in clinical use. These characteristics make HOCl particularly suitable for populations with sensitive tissues, including children, elderly patients, and those with compromised immune function (Wang et al., 2020).

Implementing HOCl in Oropharyngeal Care

Successful integration of HOCl into oropharyngeal care protocols requires attention to product quality, formulation specificity, and appropriate application techniques.

• Product Selection: Utilize sterile, pharmaceutical-grade HOCl solutions specifically formulated for oral or gargle use. Not all HOCl products are equivalent; factors including pH, concentration, stability, and the presence of stabilizers significantly affect antimicrobial efficacy and tissue compatibility. Products with demonstrated stability and appropriate pH (4.0-6.5) are preferred for mucosal applications.
• Application: Follow product directions for usage (e.g., gargle for 30-60 seconds, or direct spray to affected area). Ensure thorough rinsing or coating of the throat and oropharyngeal tissues. For sore throat management, gargling 2-3 times daily or as needed for symptom relief is typically recommended. For post-surgical applications, gentle application should begin as directed by the surgeon, usually 24 hours post-operatively.
• Patient Education: Inform patients about HOCl’s benefits, including its pathogen-neutralizing capabilities, soothing properties, and excellent safety profile. Emphasize that HOCl is naturally produced by the body’s immune system, which may improve patient acceptance and compliance. Address common concerns about taste and sensation, noting that HOCl solutions are generally tasteless and non-irritating.
• Storage and Stability: HOCl solutions should be stored according to manufacturer recommendations, typically in opaque containers away from heat and light. While modern formulations offer improved stability (up to 24 months for some products), patients should be advised to check expiration dates and replace products as needed to ensure optimal efficacy (Wang et al., 2020).

Future Directions in Oropharyngeal HOCl Research

The field of HOCl application in oropharyngeal medicine continues to evolve, with several promising areas of investigation emerging. Researchers are exploring optimized delivery systems, including sustained-release formulations and nanoparticle-based carriers that could prolong contact time with mucosal surfaces. Additionally, the potential role of HOCl in managing biofilm-associated chronic tonsillitis and recurrent pharyngitis is under investigation, as these conditions represent significant clinical challenges with limited current therapeutic options.

The COVID-19 pandemic has renewed interest in oropharyngeal antiseptics as potential tools for reducing viral transmission. Preliminary evidence suggests that HOCl may reduce SARS-CoV-2 viral load in the oropharynx, though larger clinical trials are needed to confirm these findings and establish clinical protocols (Tazawa et al., 2023). Furthermore, the potential for HOCl to serve as an antibiotic-sparing agent in pharyngitis management aligns with global antimicrobial stewardship initiatives and could help reduce unnecessary antibiotic prescriptions.

Conclusion

HOCl represents a significant advancement in the management of throat and oropharyngeal conditions. Its powerful yet gentle antimicrobial action makes it an effective tool for combating pathogens responsible for sore throats, URIs, and oral thrush, while also supporting post-operative recovery and general oral hygiene. The growing body of clinical evidence supports HOCl’s superiority over many conventional antiseptics in terms of both efficacy and tolerability. Compared to traditional remedies and antiseptics, HOCl offers a superior combination of broad-spectrum antimicrobial activity, anti-inflammatory effects, excellent safety, and microbiome compatibility, positioning it as a valuable agent for enhancing oropharyngeal health and immune defense. As research continues to expand our understanding of HOCl’s therapeutic potential, it is poised to become an increasingly important tool in otolaryngological practice. Explore our information on wound-care and skin-treatment for comprehensive health solutions.

Frequently Asked Questions (FAQ)

Q1: What is HOCl and how can it help with throat infections?

A1: HOCl is a natural antimicrobial agent produced by the body’s immune cells (neutrophils) during the immune response to infection. It effectively neutralizes a wide range of bacteria and viruses that cause sore throats and oropharyngeal infections, providing both antimicrobial action and soothing relief. Clinical studies have demonstrated its efficacy in reducing sore throat symptoms and accelerating recovery (Gun, 2018).

Q2: Is HOCl safe to use as a throat gargle or mouth rinse?

A2: Yes, pharmaceutical-grade HOCl solutions formulated for oral use are sterile, non-irritating, and non-toxic to human mucosal cells. Extensive safety data from clinical trials confirm excellent tolerability with minimal to no adverse effects, even with repeated use (Sakarya et al., 2014; Wang et al., 2020).

Q3: How does HOCl compare to Chlorhexidine (CHX) for throat care?

A3: HOCl offers similar broad-spectrum antimicrobial benefits to CHX but without the risk of tooth staining, altered taste, or mucosal irritation. Research has shown HOCl to be superior to CHX in reducing oral biofilm viability without adverse effects on dental hard tissues, making it a more comfortable and potentially safer option for regular use (Aherne et al., 2022).

Q4: Can HOCl help with viral sore throats or just bacterial ones?

A4: HOCl is effective against a broad spectrum of pathogens, including many viruses (coronaviruses, influenza, rhinoviruses) and bacteria, making it potentially beneficial for both viral and bacterial causes of sore throats and oropharyngeal infections. Its virucidal activity has been demonstrated against SARS-CoV-2 surrogates in laboratory studies (Tazawa et al., 2023).

Q5: Are there any side effects of using HOCl for throat applications?

A5: HOCl is generally well-tolerated with minimal to no side effects due to its gentle, non-cytotoxic nature. Unlike alcohol-based or iodine-based products, it does not cause burning, stinging, or tissue damage upon application to inflamed mucosal surfaces.

Q6: Can HOCl help prevent upper respiratory infections like colds or flu?

A6: By reducing the microbial load in the oropharynx, HOCl may help limit the initial colonization of viruses and bacteria, potentially contributing to the prevention or reduction of severity of upper respiratory infections. However, it should be considered as part of a comprehensive hygiene approach rather than a standalone preventative measure. Further clinical research is needed to establish specific prevention protocols.

References

Aherne, O., Ortiz, R., Fazli, M. M., & Davies, J. R. (2022). Effects of stabilized hypochlorous acid on oral biofilm bacteria. BMC Oral Health, 22(1), 415. https://doi.org/10.1186/s12903-022-02435-4

Cooper, L., & McGeorge, G. (2016). Post-tonsillectomy management: A framework. Australian Family Physician, 45(5), 289–293.

Fedorowicz, Z., van Zuuren, E. J., Nasser, M., Carter, B., & Al Langawi, J. H. (2020). Oral rinses, mouthwashes and sprays for improving recovery following tonsillectomy. Cochrane Database of Systematic Reviews, 2020(3), CD007806. https://doi.org/10.1002/14651858.CD007806.pub2

Goodman, J. (2024, March 15). Hypochlorous acid and game changing paradigms in medicine and dentistry. Oral Health Group. https://www.oralhealthgroup.com/features/hypochlorous-acid-and-game-changing-paradigms-in-medicine-and-dentistry

Gun, T. (2018). Efficacy of low-concentration hypochlorous acid spray in acute sore throat relief. The Annals of Eurasian Medicine, 7(3), 134–138. https://doi.org/10.4328/aemed.134

Lin, Y.-C., Tsai, C.-F., & Huang, H.-L. (2023). Effects of hypochlorous acid mouthwash on salivary bacteria including Staphylococcus aureus in patients with periodontal disease: A randomized controlled trial. BMC Oral Health, 23(1), 698. https://doi.org/10.1186/s12903-023-03358-4

Sakarya, S., Gunay, N., Karakulak, M., Ozturk, B., & Ertugrul, B. (2014). Hypochlorous acid: An ideal wound care agent with powerful microbicidal, antibiofilm, and wound healing potency. Wounds, 26(12), 342–350.

Tazawa, K., Jadhav, R., Azuma, M. M., & Fenno, J. C. (2023). Hypochlorous acid inactivates oral pathogens and a SARS-CoV-2-surrogate. BMC Oral Health, 23(1), 121. https://doi.org/10.1186/s12903-023-02820-7

Wang, L., Roman, M., & Bassiri, M. (2020). Status report on topical hypochlorous acid: Clinical relevance of specific formulations, potential modes of action, and study outcomes. Journal of Wound Care, 29(Suppl 5a), S1–S16. https://doi.org/10.12968/jowc.2020.29.S5a.01